Ignite Creation Date:
2024-05-06 @ 3:30 PM
Last Modification Date:
2024-10-26 @ 1:51 PM
Study NCT ID:
NCT04654975
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2020-12-03
Brief Title:
Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer METABREC
Sponsor:
Universitaire Ziekenhuizen KU Leuven
Organization:
Universitaire Ziekenhuizen KU Leuven
Study Overview
Official Title:
Risk Factors and Treatment Options for Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer a Multicentric Retrospective Cohort Study METABREC
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
Recruiting
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
METABREC
Brief Summary:
Esophagectomy is the cornerstone of the curative treatment of esophageal carcinoma Despite this treatment patients can suffer from locoregional or distant metastatic disease and only a very selected group of patients can be cured mostly those with recurrence in one single organ
Brain metastases are rare after esophagectomy for cancer but they have a serious impact on survival Agressive treatment is often moren difficult for brain metastases compared to other metastases and some risk factors have been identified earlier
There is an impression that the incidence of brain metastases in esophageal cancer patients has increased since the introduction of neoadjuvant treatment schemes However this is not clear yet A potential explanation could be that chemotherapy disturbs the blood-brain-barrier hereby facilitating the migration of tumor cells to the brain
The purpose of this study is to retrospectively analyze the incidence and potential risk factors of brain metastases in patients who underwent esophagectomy for esophageal cancer Patients treated between 2000 and 2019 will be included and outcome parameters are Odds Ratio for brain metastases comparison between primary surgery and neoadjuvant treatment followed by surgery time to recurrence and risk factors number and characteristics of the brain metastases
Brain metastases are rare after esophagectomy for cancer but they have a serious impact on survival Agressive treatment is often moren difficult for brain metastases compared to other metastases and some risk factors have been identified earlier
There is an impression that the incidence of brain metastases in esophageal cancer patients has increased since the introduction of neoadjuvant treatment schemes However this is not clear yet A potential explanation could be that chemotherapy disturbs the blood-brain-barrier hereby facilitating the migration of tumor cells to the brain
The purpose of this study is to retrospectively analyze the incidence and potential risk factors of brain metastases in patients who underwent esophagectomy for esophageal cancer Patients treated between 2000 and 2019 will be included and outcome parameters are Odds Ratio for brain metastases comparison between primary surgery and neoadjuvant treatment followed by surgery time to recurrence and risk factors number and characteristics of the brain metastases
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None